Preventing tumors from shedding their identifying proteins allows immune system to attack

March 30, 2018 by Bob Yirka, Medical Xpress report
Histological analysis (Fontana-Masson staining) of lung tissue demonstrated an apparent reduction in the number and size of metastases in mice that were treated with the MICA antibody (representative of five mice). Credit: Science (2018). DOI: 10.1126/science.aao0505

A team of researchers with the Dana-Farber Cancer Institute and Brigham and Women's Hospital in the U.S. has found that introducing an antibody into a cancerous mouse model prevented the escape of ligands from a tumor surface allowing natural killer cells to attack. In their paper published in the journal Science, the group describes their technique and how well it worked. Lewis Lanier with Heidelberg University, Medical Faculty Mannheim in Germany offers an overview of the work done by the team in a Perspective piece in the same journal issue and also gives an overview of immunotherapy research in general.

Prior research has shown that one of the reasons the immune system has trouble recognizing tumors as a threat is the their tendency to shed proteins that the immune system uses to identify them. In this new effort, the researchers focused on MICA and MICB, proteins that are produced by tumors and wind up on their exposed surfaces, which the immune system would normally be able to identify. But before that can happen, the tumor actually produces an enzyme that separates the proteins from the tumor —essentially shedding them and preventing the immune system from using them as a signal to go on the offensive. In this new effort, the researchers looked into whether there might be a way to prevent tumors from shedding such proteins, thereby allowing the immune system to do its work.

After some searching, the team settled on an antibody called mAb 7C6—they found that when applied to mouse models with lung cancer and melanoma, the antibody caused levels of both MICA and MICB to increase on tumor surfaces, suggesting that the tumor had been unsuccessful in shedding them. Furthermore, they also found that killer immune cells were then alerted to the tumor and attacked it, which, the researchers report, resulted in a reduced load.

The technique, Lanier notes, is one of many that are being developed to help the immune system fight tumors, rather than attacking tumors directly via medical interventions. Such therapies, it is believed, will have fewer undesirable side-effects.

Explore further: Researchers develop novel immunotherapy to target colorectal cancer

More information: Lucas Ferrari de Andrade et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity, Science (2018). DOI: 10.1126/science.aao0505

Abstract
MICA and MICB are expressed by many human cancers as a result of cellular stress, and can tag cells for elimination by cytotoxic lymphocytes through natural killer group 2D (NKG2D) receptor activation. However, tumors evade this immune recognition pathway through proteolytic shedding of MICA and MICB proteins. We rationally designed antibodies targeting the MICA α3 domain, the site of proteolytic shedding, and found that these antibodies prevented loss of cell surface MICA and MICB by human cancer cells. These antibodies inhibited tumor growth in multiple fully immunocompetent mouse models and reduced human melanoma metastases in a humanized mouse model. Antitumor immunity was mediated mainly by natural killer (NK) cells through activation of NKG2D and CD16 Fc receptors. This approach prevents the loss of important immunostimulatory ligands by human cancers and reactivates antitumor immunity.

Related Stories

Researchers develop novel immunotherapy to target colorectal cancer

February 13, 2018
A Yale-led research team has developed an antibody that blocks tumors in animal models of colorectal cancer. If the finding is confirmed in clinical trials, the antibody-based treatment could become an effective weapon against ...

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Researchers discover new approach to stimulate an immune response against tumor cells

January 30, 2018
New drugs that activate the immune system to target cancer cells have improved the lives of many patients with cancer. However, immunotherapies are not effective in all patients, and the success of these therapies depends ...

Colorectal cancers may mutate to escape immune system detection in many ways

October 30, 2017
Whole exome sequencing revealed that colorectal cancers with high mutational load (MSI-H) predominantly use "immunoediting" to escape immune surveillance while colorectal cancers with low mutational load (MSS) use oncogenic ...

Researchers uncover novel mechanism by which tumors evade cancer immunotherapies

November 10, 2017
A Ludwig Cancer Research study led by Benoit Van den Eynde, Director of Ludwig Brussels, has identified a novel mechanism by which tumors of the aggressive skin cancer melanoma can resist cancer immunotherapy. Their paper, ...

Targeting blood vessels to improve cancer immunotherapy

April 12, 2017
EPFL scientists have improved the efficacy of cancer immunotherapy by blocking two proteins that regulate the growth of tumor blood vessels.

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.